UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (JAZZ) to Neutral from Buy with a price target of $188, up from $163. Following the strong Phase 3 GEA update and a 25% stock move, Jazz now appears fairly valued with a balanced risk/reward profile, the analyst tells investors in a research note. The positive study meaningfully improves the outlook, but with recent oncology momentum already reflected in the valuation and no major catalysts ahead, UBS sees limited upside/downside.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges
- Zymeworks price target raised to $40 from $30 at Stifel
- Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market Outlook
- Truist ups Jazz Pharmaceuticals price target, says Ziihera is pipeline-in-a drug
- Jazz Pharmaceuticals price target raised to $209 from $160 at Baird